TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency

Conditions

Prostate

Phase III

What is the purpose of this trial?

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

  • Ages
    18 years and older
  • Gender
    Male only
  • Trial with
    Clovis Oncology, Inc.
  • Start Date
    06/04/2018
  • End Date
    02/27/2022
Trial Image

For more information about this study, contact:

Matthew Piscatelli

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    12/05/2018
  • Study HIC
    #2000020657